Perspectives
CME Article: Chronic and Noncrisis Pain in Sickle Cell Disease
Abstract
Hospital care for pain crises has been the most studied phenomenon in sickle cell disease (SCD) and is exceptionally costly to the healthcare system.1–4 Hospitalizations likely represent a small subset of the total burden of SCD pain, however. Close investigation of the pain experience of adults with SCD has revealed that most crisis pain is managed at home; hence, much of the literature citing crisis frequency as synonymous with hospitalization represents a significant undercounting of these events.5This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Carroll CP, Haywood C, Jr Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009;84:666-670.
2. Carroll CP, Haywood C, Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med 2011;6:248-255.
3. Lanzkron S, Carroll CP, Haywood C, Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol 2010;85:797-799.
4. Lanzkron S, Haywood C, Jr Segal JB, et al. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006;81:927-932.
5. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008;148:94-101.
6. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain 2009;145:246-251.
7. Molokie RE, Wang ZJ, Wilkie DJ. Presence of neuropathic pain as an underlying mechanism for pain associated with cold weather in patients with sickle cell disease. Med Hypotheses 2011;77:491-493.
8. Coghill RC. Individual differences in the subjective experience of pain: new insights into mechanisms and models. Headache 2010;50:1531-1535.
9. Finan PH, Buenaver LF, Bounds SC, et al. Quantitative sensory tests of central sensitization are associated with discordance between pain and radiographic severity in knee osteoarthritis. Arthritis Rheum 2012; Sep.
10. Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain 2006;10:423-433.
11. Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009;301:2099-2110.
12. Choiniè M, Dion D, Peng P, et al. The Canadian STOP-PAIN project-part 1: who are the patients on the waitlists of multidisciplinary pain treatment facilities? Can J Anaesth 2010;57:539-548.
13. Kernan T, Rainville J. Observed outcomes associated with a quota-based exercise approach on measures of kinesiophobia in patients with chronic low back pain. J Orthop Sports Phys Ther 2007;37:679-687.
14. Sogutlu A, Levenson JL, McClish DK, et al. Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES project. Psychosomatics 2011;52:272-279.
15. Anie KA. Psychological complications in sickle cell disease. Br J Haematol 2005;129:723-729.
16. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med 2008;70:192-196.
17. Smith WR, McClish DK, Dahman BA, et al. Daily home opioid use in adults with sickle cell disease: the PiSCES project. J Opioid Manag 2015;11:243-253.
18. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood 2010;116:456-465.
19. Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000;96:2451-2459.
20. Krishnan S, Setty Y, Betal SG, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol 2010;148:797-804.
21. Graido-Gonzalez E, Doherty JC, Bergreen EW, et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998;92:2551-2555.
22. Cataldo G, Rajput S, Gupta K, et al. Sensitization of nociceptive spinal neurons contributes to pain in a transgenic model of sickle cell disease. Pain 2015;156:722-730.
23. Brandow AM, Stucky CL, Hillery CA, et al. Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol 2013;88:37-43.
24. Campbell CM, Moscou-Jackson G, Carroll CP, et al. An evaluation of central sensitization in patients with sickle cell disease. J Pain 2016;17:617-627.
25. Hollins M, Stonerock GL, Kisaalita NR, et al. Detecting the emergence of chronic pain in sickle cell disease. J Pain Symptom Manage 2012;43:1082-1093.
26. Garrison SR, Kramer AA, Gerges NZ, et al. Sickle cell mice exhibit mechanical allodynia and enhanced responsiveness in light touch cutaneous mechanoreceptors. Mol Pain 2012;8:62.
27. Hillery CA, Kerstein PC, Vilceanu D, et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood 2011;118:3376-3383.
28. Michaels LA, Ohene-Frempong K, Zhao H, et al. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 1998;92:3148-3151.
29. Liem RI, O’ MR, Brown DL. Effect of red cell exchange transfusion on plasma levels of inflammatory mediators in sickle cell patients with acute chest syndrome. Am J Hematol 2004;76:19-25.
30. Dworkis DA, Klings ES, Solovieff N, et al. Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. Am J Hematol 2011;86:220-223.
31. Khodorova A, Montmayeur JP, Strichartz G. Endothelin receptors and pain. J Pain 2009;10:4-28.
32. Zappia KJ, Garrison SR, Hillery CA, et al. Cold hypersensitivity increases with age in mice with sickle cell disease. Pain 2014;155:2476-2485.
33. Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000;92:465-472.
34. Celerier E, Laulin JP, Corcuff JB, et al. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001;21:4074-4080.
35. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003;97:810-815.
36. Vorobeychik Y, Chen L, Bush MC, et al. Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008;9:724-727.
37. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001;63:139-146.
38. Hay JL, White JM, Bochner F, et al. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain 2009;10:316-322.
39. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-130.
40. Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147-159.
41. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009;360:1226-1237.
